Small Cap Stocks To Follow Now - September 1st

Key Points

• MarketBeat identified seven small-cap stocks to watch: ProShares UltraPro Short QQQ, GoPro, bioAffinity Technologies, AltC Acquisition, Spring Valley Acquisition, Alumis, and Hyperliquid Strategies, based on their recent trading volume.
• The list spans several high-risk sectors and investment types, including an inverse Nasdaq-100 ETF, consumer electronics, biotechnology, clinical-stage pharmaceuticals, and special-purpose acquisition companies.
• Small-cap stocks may offer greater growth potential than larger companies, but investors should also expect higher volatility and risk; SQQQ is particularly positioned as a bearish hedging instrument because it targets three times the inverse daily performance of the Nasdaq-100.

ProShares UltraPro Short QQQ, GoPro, bioAffinity Technologies, AltC Acquisition, Spring Valley Acquisition, Alumis, and Hyperliquid Strategies are the seven Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of companies with relatively small market capitalizations, typically ranking below large- and mid-cap companies in total market value. They may offer greater growth potential than larger companies, but they also tend to involve higher volatility and investment risk. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.

ProShares UltraPro Short QQQ (SQQQ)

ProShares UltraPro Short QQQ (the Fund) seeks daily investment results, which corresponds to three times the inverse of the daily performance of the NASDAQ-100 Index (the Index). The Index includes 100 of the non-financial domestic and international issues listed on National Association of Securities Dealers Automated Quotation (NASDAQ) Stock Market.

Read Our Latest Research Report on SQQQ

GoPro (GPRO)

GoPro, Inc. develops and sells cameras, mountable and wearable accessories, and subscription services and software in the Americas, Europe, the Middle East, Africa, the Asia and Pacific region, and internationally. The company provides cloud connected HERO12 Black, HERO11 Black, HERO11 Black Mini, HERO10 Black, HERO10 Black Bones, and HERO9 Black waterproof cameras; MAX, a 360-degree waterproof camera; Premium and Premium+ subscription services, which include full access to the Quik app, cloud storage supporting source video and photo quality, camera replacement, and damage protection; Quik subscription that offers access to editing tools, which allows users to edit photos, videos, and create cinematic stories; and Quik desktop and mobile apps that enable users to get their favorite photos and videos with footage from any phone or camera.

Read Our Latest Research Report on GPRO

bioAffinity Technologies (BIAF)

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.

Read Our Latest Research Report on BIAF

AltC Acquisition (ALCC)

AltC Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was formerly known as Churchill Capital Corp VIII and changed its name to AltC Acquisition Corp.

Read Our Latest Research Report on ALCC

Spring Valley Acquisition (SV)

Read Our Latest Research Report on SV

Alumis (ALMS)

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

Read Our Latest Research Report on ALMS

Hyperliquid Strategies (PURR)

Read Our Latest Research Report on PURR

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source